Sujatha Menon

728 EFFICACY OF ETRASIMOD IN BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE PATIENTS WITH MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE GLADIATOR TRIAL

Andres J. Yarur, Marla C. Dubinsky, David T. Rubin, Alissa Walsh et autres

728 EFFICACY OF ETRASIMOD IN BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE PATIENTS WITH MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE GLADIATOR TRIAL

Andres J. Yarur, Marla C. Dubinsky, David T. Rubin, Alissa Walsh et autres

Mo1514 ETRASIMOD EFFICACY IN PATIENTS WITH MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS: POOLED RESULTS FROM THE ELEVATE UC AND GLADIATOR TRIALS

David T. Rubin, Marla C. Dubinsky, Andres J. Yarur, Alissa Walsh et autres

Mo1514 ETRASIMOD EFFICACY IN PATIENTS WITH MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS: POOLED RESULTS FROM THE ELEVATE UC AND GLADIATOR TRIALS

David T. Rubin, Marla C. Dubinsky, Andres J. Yarur, Alissa Walsh et autres

Population pharmacokinetics of tofacitinib in patients with active ankylosing spondylitis

Shinichi Tsuchiwata, Akiyuki Suzuki, Qiang Wang, Keith S. Kanik et autres

OBJECTIVE: To characterize tofacitinib pharmacokinetics (PK) in patients with active ankylosing spondylitis (AS) and estimate the effects of covariates on variability of PK parameters. MATERIALS AND METHODS: ). Covariates evaluated: baseline age, sex, race, creatinine clearance (BCCL), and C-reactive protein for CL/F; …

Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease

Jon T. Giles, Christina Charles‐Schoeman, Maya H Buch, Maxime Dougados et autres

us, gb, fr, hu, es (code pays fourni par la source)

798: THE EFFICACY AND SAFETY OF ETRASIMOD IN MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE GLADIATOR TRIAL

Silvio Danese, Martina Goetsch, Laurent Peyrin‐Biroulet, Andrés Yarur et autres

Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis—A Safety Analysis

Anita Afzali, Miguel Regueiro, Andrés Yarur, Yamile Zabana et autres

BACKGROUND: receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO). Coadministration of drugs that inhibit MAO with opioids and antidepressants …

us, es, hk, gb, ch, in, fr (code pays fourni par la source)

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Atul Deodhar, Servet Akar, Jeffrey R. Curtis, Bassel Elzorkany et autres

OBJECTIVES: Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). METHOD: Pooled data from Phase 2 (NCT01786668; 04/2013-03/2015)/Phase 3 (NCT03502616; 06/2018-08/2020) RCTs in AS patients were analyzed (3 overlapping cohorts): 16-week placebo-controlled (tofacitinib …

us, tr, Égypte, gb, ca, nl (code pays fourni par la source)

Exposure–Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies

Sujatha Menon, Satoshi Shoji, Shinichi Tsuchiwata, Lara Fallon et autres

Abstract Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). These post hoc exposure–response (E–R) analyses of pooled data from two Phase 3 studies (NCT01877668 and NCT01882439) characterized the relationships between tofacitinib exposure and efficacy (American College …

us, jp, ca (code pays fourni par la source)

Su1797 ETRASIMOD SHOWS LOW RISK OF ADVERSE EVENTS FOLLOWING CONCOMITANT USE WITH OPIOIDS OR ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

Anita Afzali, Miguel Regueiro, Andrés Yarur, Yamile Zabana et autres

Advancing the utilization of real‐world data and real‐world evidence in clinical pharmacology and translational research—Proceedings from the ASCPT 2023 preconference workshop

Jing Liu, Karen Rowland Yeo, Almut G. Winterstein, Simon Dagenais et autres

Real-world data (RWD) and real-world evidence (RWE) are now being routinely used in epidemiology, clinical practice, and post-approval regulatory decisions. Despite the increasing utility of the methodology and new regulatory guidelines in recent years, there remains a lack of awareness of how …

us, gb, de (code pays fourni par la source)